Cote d'Ivoire vs Mozambique: Access to anti-retroviral drugs, female
Cote d'Ivoire
84.0%
in 2024
Mozambique
85.0%
in 2024
Cote d'Ivoire rank
50th
Mozambique rank
49th
Access to anti-retroviral drugs, female over time
- Cote d'Ivoire
- Mozambique
How they compare
Mozambique currently reports 85.0% against 84.0% in Cote d'Ivoire, a difference of 1.0%.
The two have swapped places 4 times across 25 shared years of data; in 2000 it was Mozambique ahead.
Cote d'Ivoire ranks 50th and Mozambique ranks 49th of 141 countries.
Cote d'Ivoire has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.8% | 3.4% | 1.4% | Cote d'Ivoire |
| 2010s | 41.6% | 41.4% | 0.2% | Cote d'Ivoire |
| 2020s | 78.2% | 76.6% | 1.6% | Cote d'Ivoire |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Cote d'Ivoire or Mozambique?
- Mozambique, at 85.0% against 84.0% in Cote d'Ivoire as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Cote d'Ivoire and Mozambique?
- 1.0%, with Mozambique ahead.
- How many years of comparable data are there for Cote d'Ivoire and Mozambique?
- 25 years are reported by both, from 2000 to 2024.
- How do Cote d'Ivoire and Mozambique rank globally for access to anti-retroviral drugs, female?
- Cote d'Ivoire ranks 50th and Mozambique ranks 49th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.